Topics

NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma

20:00 EDT 30 Apr 2019 | AAAS

(dna Communications) Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.

Original Article: NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma

NEXT ARTICLE

More From BioPortfolio on "NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma"

Quick Search

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...